NCT07652294
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentSpyre Therapeutics, Inc.
~645 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:SPY001SPY002SPY003
At a glance
Recruiting sites
0 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants who experienced an adverse event
Measured over Week 96
Conditions
Where it's being run
15 sites across 9 statesPoland5
Georgia3
Texas1
Czechia1
Greece1
Serbia1
Gangwon-do1
South Korea1
Study leadership
- SKYLINE Study Director · STUDY_DIRECTOR · Spyre Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Percentage of participants who experienced an adverse eventWeek 96
Incidence of treatment-emergent adverse events (TEAEs) as measured over time.